Peroxisome Proliferator Receptor gamma Agonist [phsu]
Activated [acty]
rosiglitazone [orch, phsu]
Bone Resorption [ortf]
Women [popg]
Type 2 Diabetes [dsyn]
randomized [resa]
Controlled [ftcn]
Trial [resa]
Previous [tmco]
weeks [tmco]
Exposure NOS [inpo]
rosiglitazone [orch, phsu]
pioglitazone [orch, phsu]
Circulating [ftcn]
Marker [clna]
Bone Formation [ortf]
Procollagen [aapp, bacs]
Terminal [tmco]
Propeptide [aapp]
P1NP [lbpr]
Osteocalcin [aapp, bacs]
Bone Specific Alkaline Phosphatase [lbpr]
Decreased [qnco]
bone markers [medd]
Resorption [orgf]
Examined [fndg]
rosiglitazone [orch, phsu]
Bone Resorption [ortf]
formation [biof]
Marker [clna]
weeks [tmco]
Post [tmco]
DOUBLE BLIND [resa]
placebo [topp]
controlled randomized trial [inpr, resa]
Evaluated [ftcn]
effects [qlco]
months [tmco]
rosiglitazone [orch, phsu]
placebo [topp]
Circulating [ftcn]
Marker [clna]
Bone [bpoc]
turnover [qnco]
Patients [podg]
Type 2 Diabetes [dsyn]
Cardiovascular disease [dsyn]
Additional [ftcn]
Cardiac [bpoc]
risk factors [qnco]
Principal [qlco]
End Point [qlco]
Bone Formation [ortf]
Resorption [orgf]
Marker [clna]
Measured [qlco]
P1NP [lbpr]
Carboxy [orch]
Terminal [tmco]
Cross link [npop]
CTX [gngm]
Subject [grup]
COMPLETED [qlco]
Study [mnob]
baseline [bodm]
Age [orga]
Including [ftcn]
Women [popg]
Black [popg]
Hispanic [popg]
Six [qnco]
Subject [grup]
Distributed [ftcn]
placebo [topp]
rosiglitazone [orch, phsu]
Group [idcn]
Women [popg]
treated [topp]
rosiglitazone [orch, phsu]
CTX [gngm]
Levels [qlco]
Received [qlco]
placebo [topp]
P NOS [aapp, imft]
P1NP [lbpr]
OPG [gngm]
Stratified [qlco]
Men [popg]
Stratified [qlco]
Ethnicity [popg]
statistically significant [qnco]
Observed [ftcn]
CTX [gngm]
P1NP [lbpr]
OPG [gngm]
OHD [dsyn]
treatment [ftcn]
Group [idcn]
Women [popg]
Take [hlca]
rosiglitazone [orch, phsu]
Circulating [ftcn]
Marker [clna]
Bone Resorption [ortf]
Prior [tmco]
Short duration [qlco]
Principal [qlco]
Decrease [qlco]
Marker [clna]
Bone Formation [ortf]
